• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Dr. Suzan Obagi Appointed as Chief Medical Director at Obagi Cosmeceuticals, a Subsidiary of Waldencast plc.

    2/20/24 9:00:00 AM ET
    $WALD
    Package Goods/Cosmetics
    Consumer Discretionary
    Get the next $WALD alert in real time by email

    LONG BEACH, Calif., Feb. 20, 2024 (GLOBE NEWSWIRE) -- Obagi Cosmeceuticals LLC ("Obagi"), a leader in skincare innovation and the originator of medical-grade skincare, is thrilled to announce the appointment of Dr. Suzan Obagi as the Company's first-ever Chief Medical Director. Obagi is a subsidiary of Waldencast plc, (NASDAQ:WALD) ("Waldencast"), a global multi-brand beauty and wellness platform and publicly listed company. Dr. Obagi brings a wealth of experience and expertise to her role, further solidifying Obagi's commitment to providing advanced, transformative skincare solutions.

    Dr. Suzan Obagi is a world-renowned, leading board-certified dermatologist and cosmetic surgeon, recognized for her groundbreaking contributions to the fields of dermatology, cosmetic surgery, and skincare. Throughout her illustrious career, Dr. Obagi has become a top authority in aesthetic dermatology, medical-grade skincare, anti-aging treatments, and skin health, focusing her practice across a wide range of skin types, including darker skin. In addition to her practice, Dr. Obagi has trained physicians from around the world on the latest advancements in cosmetic and laser surgery; authored articles and book chapters on skin health restoration, autologous fat augmentation, Botox and soft tissue fillers, chemical peeling, dermabrasion, and lasers; and lectured to medical specialists and surgeons across a variety of specialties including ophthalmologic, facial plastic, cosmetic, oral and maxillofacial and dermatological on many of these topics.

    In her role of Chief Medical Director, Dr. Obagi will play a pivotal role in shaping Obagi's product development, portfolio refinement, research initiatives, and educational programs to ensure Obagi continues to provide the gold standard for skincare to the physician-dispensed market. Her extensive knowledge of dermatology and aesthetic medicine, as well as her commitment to evidence-based practices, will contribute to the continued growth and success of Obagi as a global skincare leader.

    "I am thrilled to be taking on a more formal role at Obagi as the Company's first-ever Chief Medical Director," said Dr. Suzan Obagi. "Obagi has an incredible reputation for delivering high-quality, medical-grade skincare solutions. In this new position, I am looking forward to impacting upstream product development to deliver new innovations that solve more skin concerns for more patients and consumers, as well as educating the professional community on Obagi's transformational, science-backed skincare solutions."

    As a pioneer in the skincare industry, Obagi is known for its targeted medical-grade solutions that provide transformative results. For example, its Obagi Nu-Derm® System, Professional-C®, ELASTIderm®, and Obagi Nu-Cil™ product portfolios treat common skin concerns, including hyperpigmentation, fine lines and wrinkles, hydration, brightening skin, and acne. Dr. Obagi's appointment reflects Obagi's dedication to staying at the forefront of scientific advancements in skincare and delivering unparalleled results through innovative products to its diverse customers.

    "We are honored to deepen our relationship with Dr. Suzan Obagi as she assumes the role of Obagi's inaugural Chief Medical Director," said Jordan Meyer, President of Obagi. "Dr. Obagi has been connected to our brand, in various capacities, since its inception." Meyer added, "Her deep understanding of dermatology, commitment to patient care, and passion for advancing skincare reflect Obagi's expertise and legacy in providing science-backed, physician-dispensed skincare solutions that empower individuals to achieve healthy, beautiful skin. We look forward to the positive impact her expertise will have on our team, products, and the overall skincare experience for our customers."

    About Obagi Cosmeceuticals

    Obagi Cosmeceuticals is an industry-leading, advanced skincare line rooted in research and skin biology, refined with a legacy of 30 years' experience. First known as leaders in the treatment of hyperpigmentation with the Obagi Nu-Derm® System, Obagi products are designed to diminish the appearance of premature aging, photodamage, skin discoloration, acne, and sun damage. Backed by science and trusted by professionals, Obagi empowers individuals to achieve healthy, beautiful skin.

    More information about Obagi is available on the brand's website, https://www.obagi.com.

    About Waldencast

    Founded by Michel Brousset and Hind Sebti, Waldencast's ambition is to build a global best-in-class beauty and wellness operating platform by developing, acquiring, accelerating, and scaling conscious, high-growth purpose-driven brands. Waldencast's vision is fundamentally underpinned by its brand-led business model that ensures proximity to its customers, business agility, and market responsiveness, while maintaining each brand's distinct DNA. The first step in realizing its vision was the business combination with Obagi Cosmeceuticals and Milk Makeup. As part of the Waldencast platform, its brands will benefit from the operational scale of a multi-brand platform; the expertise in managing global beauty brands at scale; a balanced portfolio to mitigate category fluctuations; asset-light efficiency; and the market responsiveness and speed of entrepreneurial indie brands. For more information please visit: https://ir.waldencast.com/.

    About Suzan Obagi, MD

    Suzan Obagi, MD Obagi is an Associate Professor of Dermatology and Plastic Surgery at the University of Pittsburgh Medical Center (UPMC) and serves as the director of the state-of-the-art UPMC Cosmetic Surgery and Skin Health Center. Dr. Obagi's academic commitments include clinical research, training residents in dermatologic surgery & cosmetic dermatologic surgery, and in her role as the director of the cosmetic dermatologic surgery fellowship.

    Dr. Obagi has worked on various committees with the American Society for Dermatologic Surgery, has formerly served as vice president of the American Board of Cosmetic Surgery and the President of the American Academy of Cosmetic Surgery, and is a past president of the Cosmetic Surgery Foundation. In addition, Dr. Obagi trains physicians from around the world on the latest in cosmetic and laser surgery.

    Media Contact:

    Sarah Montalto

    Managing Director, ICR

    [email protected]

    A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/a110ce38-015f-4b19-a397-7661f34e7953



    Primary Logo

    Get the next $WALD alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $WALD

    DatePrice TargetRatingAnalyst
    4/22/2025$5.00Buy
    Alliance Global Partners
    12/16/2024$4.30Hold
    TD Cowen
    10/25/2024$5.00Buy
    Canaccord Genuity
    5/1/2024$10.00 → $8.00Outperform
    Telsey Advisory Group
    7/24/2023Outperform → Mkt Perform
    Raymond James
    9/9/2022$12.00Buy
    DA Davidson
    8/22/2022$11.00Outperform
    Raymond James
    8/17/2022$11.00Buy
    Jefferies
    More analyst ratings

    $WALD
    SEC Filings

    View All

    SEC Form 6-K filed by Waldencast plc

    6-K - Waldencast plc (0001840199) (Filer)

    8/18/25 5:27:55 PM ET
    $WALD
    Package Goods/Cosmetics
    Consumer Discretionary

    SEC Form 6-K filed by Waldencast plc

    6-K - Waldencast plc (0001840199) (Filer)

    7/23/25 6:50:54 AM ET
    $WALD
    Package Goods/Cosmetics
    Consumer Discretionary

    SEC Form 6-K filed by Waldencast plc

    6-K - Waldencast plc (0001840199) (Filer)

    5/14/25 7:00:36 AM ET
    $WALD
    Package Goods/Cosmetics
    Consumer Discretionary

    $WALD
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Alliance Global Partners initiated coverage on Waldencast plc with a new price target

    Alliance Global Partners initiated coverage of Waldencast plc with a rating of Buy and set a new price target of $5.00

    4/22/25 9:24:54 AM ET
    $WALD
    Package Goods/Cosmetics
    Consumer Discretionary

    TD Cowen initiated coverage on Waldencast plc with a new price target

    TD Cowen initiated coverage of Waldencast plc with a rating of Hold and set a new price target of $4.30

    12/16/24 6:40:14 AM ET
    $WALD
    Package Goods/Cosmetics
    Consumer Discretionary

    Canaccord Genuity initiated coverage on Waldencast plc with a new price target

    Canaccord Genuity initiated coverage of Waldencast plc with a rating of Buy and set a new price target of $5.00

    10/25/24 7:48:31 AM ET
    $WALD
    Package Goods/Cosmetics
    Consumer Discretionary

    $WALD
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Waldencast Long-Term Capital Llc

    4 - Waldencast Acquisition Corp. (0001840199) (Issuer)

    7/25/22 12:43:24 PM ET
    $WALD
    Package Goods/Cosmetics
    Consumer Discretionary

    SEC Form 3 filed by new insider Festetics Tassilo

    3 - Waldencast Acquisition Corp. (0001840199) (Issuer)

    3/7/22 5:00:12 PM ET
    $WALD
    Package Goods/Cosmetics
    Consumer Discretionary

    SEC Form 3 filed by new insider Chatterley Aaron

    3 - Waldencast Acquisition Corp. (0001840199) (Issuer)

    12/23/21 4:30:38 PM ET
    $WALD
    Package Goods/Cosmetics
    Consumer Discretionary

    $WALD
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Waldencast Announces Strong Progress on Business Priorities for H1 2025 and Initiatives to Drive Transformation

    Obagi Medical delivers H1 2025 double-digit growth in its Core Strategic Channels. Novaestiq Acquisition Doubles the Brand's Addressable Market in the U.S. Milk Makeup Delivers Strong Retail Sales Performance in U.S. Retail in H1 2025 and Expands Its Digital Footprint in Q2 Company Launches an Exploration of Strategic Alternatives to Enhance Shareholder Value Company Postpones H1 2025 Earnings Release and Conference Call; Provides Update to FY 2025 Guidance LONDON, Aug. 18, 2025 (GLOBE NEWSWIRE) -- Waldencast plc (NASDAQ:WALD) ("Waldencast" or the "Company"), a global multi-brand beauty and wellness platform, today provided a business update for H1 2025 results. "Our brands

    8/18/25 5:43:47 PM ET
    $WALD
    Package Goods/Cosmetics
    Consumer Discretionary

    Waldencast Acquires Novaestiq Corp. and U.S. Rights to Leading Injectable Hyaluronic Acid Gel Line, Saypha®, Under the Obagi Medical Brand

    Acquisition strengthens Obagi Medical's product portfolio with proven, scientifically backed, injectable portfolio New products position Obagi Medical at the forefront of health, beauty and aesthetics convergence LONDON, July 23, 2025 (GLOBE NEWSWIRE) -- Waldencast plc (NASDAQ:WALD) ("Waldencast"), a global multi-brand beauty and wellness platform, today announced that it has acquired Novaestiq Corp. (Novaestiq), a growth-oriented aesthetic and medical dermatological innovations company, as well as the U.S. rights to the Saypha® line of hyaluronic acid (HA) injectable gels. The strategic acquisition expands Obagi Medical's offerings beyond U.S. medical-grade skincare, a marke

    7/23/25 6:45:00 AM ET
    $WALD
    Package Goods/Cosmetics
    Consumer Discretionary

    Shareholders Elect Four Independent Directors to the Six Flags Board

    Six Flags Entertainment Corporation (NYSE:FUN), the largest regional amusement park operator in North America, announced today that its shareholders elected Sandra (Sandy) Cochran, Michael Colglazier, Felipe Dutra, and Steven Hoffman to the Board of Directors of Six Flags Entertainment Corporation for 3-year terms expiring in 2028. Shareholders also confirmed the appointment of Deloitte & Touche LLP as the Company's independent registered public accounting firm, approved an advisory vote on the compensation of the Company's named executive officers, and confirmed a 1-year frequency for shareholder advisory votes on executive compensation. "I want to welcome Sandy, Michael, Felipe and St

    6/25/25 5:00:00 PM ET
    $BUD
    $CBRL
    $DG
    Beverages (Production/Distribution)
    Consumer Staples
    Restaurants
    Consumer Discretionary

    $WALD
    Financials

    Live finance-specific insights

    View All

    Waldencast Announces Strong Progress on Business Priorities for H1 2025 and Initiatives to Drive Transformation

    Obagi Medical delivers H1 2025 double-digit growth in its Core Strategic Channels. Novaestiq Acquisition Doubles the Brand's Addressable Market in the U.S. Milk Makeup Delivers Strong Retail Sales Performance in U.S. Retail in H1 2025 and Expands Its Digital Footprint in Q2 Company Launches an Exploration of Strategic Alternatives to Enhance Shareholder Value Company Postpones H1 2025 Earnings Release and Conference Call; Provides Update to FY 2025 Guidance LONDON, Aug. 18, 2025 (GLOBE NEWSWIRE) -- Waldencast plc (NASDAQ:WALD) ("Waldencast" or the "Company"), a global multi-brand beauty and wellness platform, today provided a business update for H1 2025 results. "Our brands

    8/18/25 5:43:47 PM ET
    $WALD
    Package Goods/Cosmetics
    Consumer Discretionary

    Waldencast Acquires Novaestiq Corp. and U.S. Rights to Leading Injectable Hyaluronic Acid Gel Line, Saypha®, Under the Obagi Medical Brand

    Acquisition strengthens Obagi Medical's product portfolio with proven, scientifically backed, injectable portfolio New products position Obagi Medical at the forefront of health, beauty and aesthetics convergence LONDON, July 23, 2025 (GLOBE NEWSWIRE) -- Waldencast plc (NASDAQ:WALD) ("Waldencast"), a global multi-brand beauty and wellness platform, today announced that it has acquired Novaestiq Corp. (Novaestiq), a growth-oriented aesthetic and medical dermatological innovations company, as well as the U.S. rights to the Saypha® line of hyaluronic acid (HA) injectable gels. The strategic acquisition expands Obagi Medical's offerings beyond U.S. medical-grade skincare, a marke

    7/23/25 6:45:00 AM ET
    $WALD
    Package Goods/Cosmetics
    Consumer Discretionary

    Waldencast Reports Q1 2025 Financial Results

    Q1 Net Revenue of $65.4 million, (4.1)% decline from Q1 202476.4% Adjusted Gross Margin, an improvement of 10 basis points$4.4 million of Adjusted EBITDA LONDON, May 13, 2025 (GLOBE NEWSWIRE) -- Waldencast plc (NASDAQ:WALD) ("Waldencast" or the "Company"), a global multi-brand beauty and wellness platform, today reported operating results for the three months ended March 31, 2025 ("Q1 2025") on Form 6-K to the U.S. Securities and Exchange Commission (the "SEC"), which are also available on our investor relations site at http://ir.waldencast.com/. Michel Brousset, Waldencast Founder and CEO, said: "As anticipated, in Q1 2025, Milk Makeup results were impacted by the cycling of the very su

    5/13/25 4:15:00 PM ET
    $WALD
    Package Goods/Cosmetics
    Consumer Discretionary

    $WALD
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13D/A filed by Waldencast plc (Amendment)

    SC 13D/A - Waldencast plc (0001840199) (Subject)

    2/9/24 6:25:08 PM ET
    $WALD
    Package Goods/Cosmetics
    Consumer Discretionary

    SEC Form SC 13G filed by Waldencast plc

    SC 13G - Waldencast plc (0001840199) (Subject)

    2/1/24 5:17:40 PM ET
    $WALD
    Package Goods/Cosmetics
    Consumer Discretionary

    SEC Form SC 13G/A filed by Waldencast plc (Amendment)

    SC 13G/A - Waldencast plc (0001840199) (Subject)

    1/31/24 10:23:25 AM ET
    $WALD
    Package Goods/Cosmetics
    Consumer Discretionary

    $WALD
    Leadership Updates

    Live Leadership Updates

    View All

    Shareholders Elect Four Independent Directors to the Six Flags Board

    Six Flags Entertainment Corporation (NYSE:FUN), the largest regional amusement park operator in North America, announced today that its shareholders elected Sandra (Sandy) Cochran, Michael Colglazier, Felipe Dutra, and Steven Hoffman to the Board of Directors of Six Flags Entertainment Corporation for 3-year terms expiring in 2028. Shareholders also confirmed the appointment of Deloitte & Touche LLP as the Company's independent registered public accounting firm, approved an advisory vote on the compensation of the Company's named executive officers, and confirmed a 1-year frequency for shareholder advisory votes on executive compensation. "I want to welcome Sandy, Michael, Felipe and St

    6/25/25 5:00:00 PM ET
    $BUD
    $CBRL
    $DG
    Beverages (Production/Distribution)
    Consumer Staples
    Restaurants
    Consumer Discretionary

    Milk Makeup to Launch at Ulta Beauty This Spring

    The New York City based award-winning clean color cosmetics brand will expand to select Ulta Beauty stores nationwide and online, marking a significant milestone since its debut in 2016 NEW YORK, Jan. 28, 2025 /PRNewswire/ -- Milk Makeup, the trailblazing clean beauty brand celebrated for its iconic, high-performance formulas, inclusive ethos and part of the Waldencast plc (NASDAQ:WALD) platform, is thrilled to announce an expansion into the nation's largest beauty retailer, Ulta Beauty. Beginning this spring, Milk Makeup's cult-favorite products, including the 13x award-winning Hydro Grip Primer and internet-breaking Cooling Water Jelly Tints will be available in 600+ Ulta Beauty stores nat

    1/28/25 6:45:00 AM ET
    $WALD
    Package Goods/Cosmetics
    Consumer Discretionary

    Waldencast Announces New "Creative Council" of Industry Pioneers and Disruptors

    NEW YORK, Feb. 22, 2024 (GLOBE NEWSWIRE) -- Waldencast plc, (NASDAQ:WALD) ("Waldencast" or "the Company"), a global multi-brand beauty and wellness platform, today announced the formation of a new Creative Council. The interdisciplinary team of industry disruptors will come together to help Waldencast stay ahead of the curve by ideating on long-term macro and micro-trends in the beauty and wellness industry, and to ensure the Company evolves to meet customer needs now and in the future. The Creative Council will focus on what is next in beauty, wellness, and culture. The goal of the powerhouse group is to provide a pulse on trends and become the dreamers and makers of what these industrie

    2/22/24 9:15:00 AM ET
    $WALD
    Package Goods/Cosmetics
    Consumer Discretionary